Select Language
Coagulation factor IX
Coagulation factor IX Overview
| English Name | Coagulation factor IX | Approved Drugs | 34 |
| Drugs in Clinical Trials | 23 | Target Synonym | Coagulation Factor IX，Plasma Thromboplastin Component，Christmas Factor，Christmas Disease，Factor IX F9，Hemophilia B，EC 3.4.21.22，F9 P22，THPH8，HEMB，FIX，P19，Factor IX，EC:3.4.21.22，F9，PTC，EC 3.4.21，Plasma Thromboplastic Component，Factor 9 |
| Highest Development Stage | Approved | ||
| English Name | Coagulation factor IX |
| Target Synonym | Coagulation Factor IX，Plasma Thromboplastin Component，Christmas Factor，Christmas Disease，Factor IX F9，Hemophilia B，EC 3.4.21.22，F9 P22，THPH8，HEMB，FIX，P19，Factor IX，EC:3.4.21.22，F9，PTC，EC 3.4.21，Plasma Thromboplastic Component，Factor 9 |
| Approved Drugs | 34 |
| Drugs in Clinical Trials | 23 |
| Highest Development Stage | Approved |
Coagulation factor IX Product List
- Product Category
Protein (2)
- Product Status
Launched (2)
- Species
Cynomolgus (1)Human (1)
- Tag
His Tag (2)
- Conjugate
Unconjugated (2)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
FIX-H52H3 |  Human | HEK293 | Human Coagulation factor IX / F9 Protein, His Tag, low endotoxin (Pro-form, MALS verified) |  |  | |
FIX-C52H9 |  Cynomolgus | HEK293 | Cynomolgus Coagulation factor IX / F9 Protein, His Tag (Pro-form, MALS verified) |  | |
Total: 2
- 1
Coagulation factor IX Background
Coagulation Factor IX is also known as F9, FIX, and P19. Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca2+ ions, phospholipids, and factor VIIIa，and plays an important role in the intrinsic blood coagulation cascade. As a key component of the clotting cascade, Factor IX helps form stable blood clots and prevents excessive bleeding.
Coagulation factor IX Synonyms
Coagulation factor Ix,PTC,F9,THPH8,FIX,Plasma Thromboplastic Component,factor Ix
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Denecimig | NNC0365-3769 A; NN0365-3769; NN 7769; Mim-8; NNC0365-3769; NN7769; NN-7769; Mim8 | Phase 3 Clinical | Novo Nordisk A/S | Hemophilia A | Details |
| Human prothrombin complex (National Drug Group Wuhan Blood) | Phase 3 Clinical | Sinopharm Wuhan Biopharmaceutical Co Ltd | Hemophilia B; Hemorrhage | Details | |
| Eptacog Alfa Biosimilar(Aryogen Pharmed) | Phase 3 Clinical | Aryogen Pharmed Co | Factor VII Deficiency; Hemophilia A | Details | |
| Human prothrombin complex concentrate (Sichuan Yuanda Shuyang Pharmaceutical) | Phase 3 Clinical | Yuanda Shuyang Life Sciences (Chengdu) Co Ltd | Blood Coagulation Disorders | Details | |
| Arvenacogene Sanparvovec | ANB-002; ANB-2 | Phase 3 Clinical | BIOCAD JSC | Hemophilia B | Details |
| Human prothrombin complex concentrate (Harbin Shiheng Bioengineering Pharmaceutical) | Phase 3 Clinical | Harbin Pacific Biopharmaceutical Co Ltd | Hemophilia B | Details | |
| Human prothrombin complex(Hunan Ziguang Huhan Nanyue Pharmaceutical) | Phase 3 Clinical | Hunan Ziguang Huhan Nanyue Pharmaceutical Co Ltd | Hemophilia B | Details | |
| aPCC-emicizumab | Phase 3 Clinical | Emory University | Hemophilia A | Details | |
| BAX-335 | BAX-335; AskBio-009 | Phase 2 Clinical | AskBio Inc, Bayer AG, Glaxosmithkline Plc | Hemophilia B | Details |
| Factor VIIa-CTP | MOD-5014; MOD-5017; OPK88005 | Phase 2 Clinical | Opko Health Inc, Prolor Biotech | Blood Coagulation Disorders, Inherited; Hemophilia A; Hemophilia B | Details |
| REGV131-LNP1265 | REGV131-LNP1265 | Phase 2 Clinical | Intellia Therapeutics Inc, Regeneron Pharmaceuticals Inc | Hemophilia B | Details |
| BE-101 | BE-101 | Phase 2 Clinical | Be Biopharma Inc | Hemophilia B | Details |
| SR-604 | SR-604; SR604 | Phase 2 Clinical | Shanghai Raas Blood Products Co Ltd | Factor VII Deficiency; Hemophilia A; Hemophilia B; Hemorrhage; von Willebrand Diseases | Details |
| FT-004 | FT-004; FT004 | Phase 2 Clinical | Frontera Therapeutics (Shanghai) Co Ltd | Hematologic Diseases; Hemophilia B | Details |
| ZS-801 | ZS801; ZS-801 | Phase 2 Clinical | Sichuan Real&Best Biotech Co Ltd | Hemophilia B | Details |
| VGB-R04 | VGB-R04 | Phase 2 Clinical | Shanghai Vitalgen BioPharma Co Ltd | Hemophilia B | Details |
| Eptacog alfa biosimilar (Valin Technologies) | Phase 1 Clinical | Valin Technologies | Hemophilia A | Details | |
| AAV2-hFIX16 | AAV2-hFIX16 | Phase 1 Clinical | Spark Therapeutics Inc | Hemophilia B | Details |
| SS-327 | GenSciences-327; 注射用培重组人凝血因子IX-Fc融合蛋白; SS327 | Phase 1 Clinical | Furen Pharmaceutical Group Co Ltd, Zhengzhou Shengsi Biotechnology Co Ltd | Hemophilia B | Details |
| NTB-001 | NTB-001 | Phase 1 Clinical | Nanjing Zhengda Tianqing Pharmaceutical Co Ltd | Hemophilia A | Details |
| Emicizumab biosimilar (Wuhan Yzy Biopharma) | Y225 | Phase 1 Clinical | Wuhan Yzy Biopharma Co Ltd | Hemophilia A; Hemorrhage | Details |
| JWK-004 | JWK004; JWK-004 | Phase 1 Clinical | Chengdu Genevector Biotechnology Co Ltd | Hemophilia B | Details |
| YUVA-GT-F901 | YUVA-GT-F901 | Phase 1 Clinical | Novartis Pharma Ag | Hemophilia B | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Anti-inhibitor coagulant complex (Baxalta) | Approved | Baxalta Incorporated | PROPLEX 600, Prothromplex, Prothromplex 600, Prothromplex 600 IE, Prothromplex 600 SV, Prothromplex 600 TV, Prothromplex 600 UI, Prothromplex NF 600, PROPLEX, Feiba, Prothromplex TOTAL | United States | Hemophilia B; Hemophilia A | Baxalta Incorporated | 1979-12-21 | Blood Coagulation Disorders; Blood Coagulation Disorders, Inherited; Cardiovascular Diseases; Heart Diseases; Hemophilia A; Hemophilia B; Hemorrhage | Details | |
| Human prothrombin complex (Nanyue Biopharming) | Approved | Hunan Ziguang Huhan Nanyue Pharmaceutical Co Ltd | Mainland China | Hemorrhage | Hunan Ziguang Huhan Nanyue Pharmaceutical Co Ltd | 2019-09-05 | Hemophilia B; Hemorrhage | Details | ||
| Eptacog alfa (Novo Nordisk) | NN-007 | Approved | Novo Nordisk A/S | NiaStase, NovoSeven, 诺其 | EU | Thrombasthenia; Factor VII Deficiency; Hemophilia A; Hemophilia B | Novo Nordisk A/S | 1996-02-23 | Acquired hemophilia; Blood Loss, Surgical; Burns; Cerebral Hemorrhage; Factor VII Deficiency; Hemophilia A; Hemophilia B; Hemorrhage; Liver Cirrhosis; Postpartum Hemorrhage; Severe Dengue; Spinal Diseases; Stroke; Thrombasthenia; Wounds and Injuries | Details |
| Etranacogene dezaparvovec | AMT-060; AAV5-hFIX; AMT-061; CSL-222; AAV5-FIX; CSL-220 | Approved | Uniqure Biopharma Bv | HEMGENIX | United States | Hemophilia B | Csl Behring | 2022-11-22 | Hemophilia B | Details |
| Human prothrombin complex (CSL Behring) | BE-1116 | Approved | Csl Behring Llc | Kcentra, Beriplex, Confidex | Japan | Vitamin K Deficiency Bleeding | Csl Behring Kk | Blood Coagulation Disorders; Coagulation Protein Disorders; Heart Diseases; Heart Failure; Hemorrhage; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Vitamin K Deficiency Bleeding; Wounds and Injuries | Details | |
| Freeze-dried activated human blood coagulation factor Ⅶ concentrate containing factor Ⅹ (Kaketsuken/KM Biologics) | MC-710 | Approved | KM Biologics Co Ltd | Byclot | Japan | Hemophilia A | KM Biologics Co Ltd | 2014-07-04 | Hemophilia A | Details |
| Human prothrombin complex concentrate (Guizhou Taibang Biological Products) | Approved | Guizhou Taibang Biological Products Co Ltd | Mainland China | Hypoprothrombinemias | Guizhou Taibang Biological Products Co Ltd | 2013-07-31 | Hypoprothrombinemias | Details | ||
| Prothrombinex-VF (CSL Behring) | Approved | Csl Behring Llc | Australia | Hemorrhage | Csl Behring Llc | 2014-10-01 | Hemorrhage | Details | ||
| Fidanacogene elaparvovec | SPK-9001; PF-06838435 | Approved | Childrens Hospital of Philadelphia | BEQVEZ, DURVEQTIX | Canada | Hemophilia B | Pfizer Inc | 2024-01-03 | Hemophilia A; Hemophilia B | Details |
| Prothrombin complex concentrate (Sanquin) | Approved | Sanquin Plasma Products Bv | Cofact | Hemorrhage | Sanquin Plasma Products Bv | 2007-11-01 | Hemorrhage | Details | ||
| Emicizumab | RG-6013; RO-5534262; ACE-910 | Approved | Chugai Pharmaceutical Co Ltd | 舒友立乐, Hemlibra | United States | Hemophilia A | Genentech Inc | 2017-11-16 | Hemophilia A; Hemorrhage; von Willebrand Disease, Type 3 | Details |
| Human Coagulation Factors IX and X (CSL Behring) | Approved | Csl Behring Llc | Factor X P Behring | Hemophilia B | Details | |||||
| Eptacog alfa biosimilar (AryoGen Biopharma) | Approved | Aryogen Biopharma | Iran | Factor VII Deficiency; Hemophilia A; Hemophilia B; Thrombasthenia | Aryogen Biopharma | 2014-01-01 | Factor VII Deficiency; Hemophilia A; Hemophilia B; Thrombasthenia | Details | ||
| Factor IX complex (Grifols) | Approved | Grifols Sa | Profilnine | United States | Hemophilia B | null | 1981-07-21 | Hemophilia B; Intracranial Hemorrhages | Details | |
| Eptacog beta | LR-769; rhFVIIa | Approved | Lfb Biotechnologies Sas, Revo Biologics Inc | Sevenfact | United States | Hemophilia A; Hemophilia B | Lfb Biotechnologies Sas | 2020-04-01 | Hemophilia A; Hemophilia B; Thrombasthenia | Details |
| Human prothrombin complex (Octapharma) | Approved | Octapharma | Ocplex, Octaplex, Pronativ | Germany | Hemorrhage | Octapharma | 2003-03-14 | Hemorrhage; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Eptacog alfa biosimilar (International Biotech Center Generium) | GNR-001 | Approved | International Biotech Center Generium | Russian Federation | Hemophilia A | International Biotech Center Generium | 2015-01-01 | Hemophilia A | Details | |
| Human prothrombin complex (LFB) | Approved | Lfb Biotechnologies Sas | KANOKAD | France | Hemorrhage | Lfb Biotechnologies Sas | 2008-09-01 | Hemorrhage | Details | |
| Human prothrombin complex (Tonrol Biopharmaceuticals) | Approved | Tonrol Bio-Pharmaceutical Co Ltd | ProthoRAAS | Mainland China | Hemorrhage | Shanghai Raas Blood Products Co Ltd | 1996-01-01 | Hemophilia B; Hemorrhage | Details | |
| Human prothrombin complex (ShenzhenWeiguang Biological Products) | Approved | Shenzhen Weiguang Biological Products Co Ltd | Mainland China | Hemorrhage | Shenzhen Weiguang Biological Products Co Ltd | 2024-05-21 | Hemophilia B; Hemorrhage | Details | ||
| Human prothrombin complex (Guangdong Shuanglin) | Approved | Guangdong Shuanglin Bio-Pharmaceutical Co Ltd | Mainland China | Hemophilia B | Guangdong Shuanglin Bio-Pharmaceutical Co Ltd | 2023-05-12 | Hemophilia B | Details | ||
| Dalnacogene Ponparvovec | BBM-H901 | Approved | Belef BioMed (Shanghai) Co Ltd | 信玖凝 | Mainland China | Hemophilia B | Shanghai Belief-Delivery BioMed Co Ltd | 2025-04-08 | Hemophilia B | Details |
| Human prothrombin complex (Shanghai Xinxing) | Approved | Shanghai Xinxing Medicine Co Ltd | Mainland China | Hemorrhage | Shanghai Xinxing Medicine Co Ltd | 1997-01-01 | Hemorrhage | Details | ||
| Human prothrombin complex (Sinopharm Shanghai Plasma) | Approved | Sinopharm Shanghai Plasma-Derived Biotherapies Co Ltd | Mainland China | Hemorrhage | Sinopharm Shanghai Plasma-Derived Biotherapies Co Ltd | 1997-01-01 | Hemorrhage | Details | ||
| Human prothrombin complex (Boya Bio-Pharmaceutical) | Approved | Boya Bio-Pharmaceutical Group Co Ltd | Mainland China | Hemorrhage | Boya Bio-Pharmaceutical Group Co Ltd | 2020-12-02 | Hemophilia B; Hemorrhage | Details | ||
| Human prothrombin complex (Guangdong Wellen) | Approved | Guangdong Wellen Pharmaceutical Co Ltd | Mainland China | Hemorrhage | Guangdong Wellen Pharmaceutical Co Ltd | 2020-10-21 | Hemophilia B; Hemorrhage | Details | ||
| Human prothrombin complex (Lanzhou Lansheng Blood Products) | Approved | Lanzhou Lansheng Blood Products Co Ltd | Mainland China | Hemophilia B | Lanzhou Lansheng Blood Products Co Ltd | 2024-09-26 | Hemophilia B | Details | ||
| Recombinant human coagulation factor VIIa N01 (Nanjing Chia-Tai Tianqing) | TQG-203 | Approved | Nanjing Zhengda Tianqing Pharmaceutical Co Ltd | Mainland China | Hemophilia A; Hemophilia B | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | 2025-06-30 | Hemophilia A; Hemophilia B | Details | |
| Factor IX (Octapharma ) | Approved | Octapharma | Octanine F 100 I.E./ml Pulver und Lösungsmittel zur Herstellung einer Injektionslösung, OCTANINE F 500 UI pulbere şi solvent pentru soluţie perfuzabilă, octanine 500TV milteliai ir tirpiklis injekciniam tirpalui, Octanine 100 IU/ml, OCTANINE, OCTANINE 500 NE por és oldószer oldatos injekcióhoz, Octanine 500 SV pulveris un šķīdinātājs injekciju šķīduma pagatavošanai, Octanine F 500 | EU | Hemophilia B | Octapharma | 2001-12-23 | Hemophilia B | Details | |
| Human prothrombin complex(Chengdu Rongsheng Pharmaceuticals) | Approved | Chengdu Rongsheng Pharmaceuticals Co Ltd | Mainland China | Coagulation Protein Disorders | Chengdu Rongsheng Pharmaceuticals Co Ltd | 2020-12-15 | Coagulation Protein Disorders; Hemophilia B | Details | ||
| Human prothrombin complex(Hebei Daan Pharmaceutical) | Approved | Hebei Daan Pharmaceutical Co Ltd | Mainland China | Hemorrhage | Hebei Daan Pharmaceutical Co Ltd | 2020-01-01 | Hemophilia B; Hemorrhage | Details | ||
| Prothrombin complex concentrat (Taibang Biological Products) | Approved | Shandong Taibang Biological Products Co Ltd | Mainland China | Hemorrhage | Shandong Taibang Biological Products Co Ltd | 2014-09-30 | Antithrombin III Deficiency; Hemorrhage | Details | ||
| Human prothrombin complex (Hualan Biological Engineering) | Approved | Hualan Ankang Biotechnology Co Ltd | Mainland China | Factor X Deficiency; Blood Coagulation Disorders | Hualan Biological Engineering Inc | 1999-01-01 | Blood Coagulation Disorders; Factor X Deficiency; Hemophilia B | Details | ||
| Human prothrombin complex concentrate (Shanxi Kangbao Biological Products) | Approved | Shanxi Kangbao Biological Product Co Ltd | Mainland China | Hemorrhage | Shanxi Kangbao Biological Product Co Ltd | 2019-09-17 | Hemophilia B; Hemorrhage | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
メールアドレス
order.jp@acrobiosystems.com
アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8